A 48-year-old woman with familial hypercholesterolaemia (FH) is started on a PCSK9 inhibitor (evolocumab) after failing to achieve LDL-C target on high-dose atorvastatin plus ezetimibe. Before initiating the PCSK9 inhibitor, which investigation is most important to establish baseline status and guide therapy?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.